Tirzepatide, marketed as Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for type 2 diabetes mellitus and chronic weight management
Common side effects of GLP-1 medications The most commonly reported side effects associated with GLP-1 receptor agonists in clinical literature include nausea, vomiting, diarrhea, constipation, and abdominal discomfort
Ribosomal protein S6 kinase B1 ( RPS6KB1 ), BRCA1 DNA repair associated ( BRCA1 ), cyclin dependent kinase 1 ( CDK1 ), ribosomal protein S3 ( RPS3 ), peroxisome proliferator-activated receptor gamma coactivator 1-alpha ( PPARGC1A/PGC-1 ), acyl-CoA synthetase long chain family member 1 ( ACSL1 ), NADH:ubiquinone oxidoreductase subunit AB1 ( NDUFAB1 ), NADH:ubiquinone oxidoreductase subunit A9 ( NDUFA9 ), ATP synthase beta chain, mitochondrial ( ATP5B ), and protein kinase AMP-activated non-catalytic subunit gamma 2 ( PRKAG2 ) were suggested to be candidate genes that may affect IMF deposition [55]

Muscle Building & Performance Increases lean mass and strength in resistance-trained adults Enhances muscle protein synthesis rates Improves exercise recovery and adaptation Reduces muscle damage markers post-exercise Tissue Repair & Recovery Accelerates healing of tendons and ligaments Enhances collagen synthesis and deposition Reduces recovery time from musculoskeletal injuries Supports surgical wound healing Metabolic Health Improves glucose disposal in insulin resistance Enhances insulin sensitivity by 34% in prediabetes Supports nutrient partitioning and utilization May reduce cardiovascular risk factors Additional Clinical Applications Important Consideration: All applications of IGF-1 LR3 are considered off-label use
Individual results vary widelysome regain 100% while others maintain 50% or more of their loss
Frequently Asked Questions Is GLP-1 agonists the same as Ozempic